Mohamed Sassi1, François Guérin2,3, Asma Zouari4, Racha Beyrouthy5,6,7, Michel Auzou2, Marguerite Fines-Guyon2, Sophie Potrel4,8, Loren Dejoies1,8, Anaïs Collet4,8, Sarrah Boukthir8, Gabriel Auger4,8, Richard Bonnet5,6,7, Vincent Cattoir1,4,8. 1. Université de Rennes 1, Inserm U1230, Rennes, France. 2. CHU de Caen, Service de Microbiologie, Caen, France. 3. Université de Caen Normandie, EA4655, Caen, France. 4. CNR de la Résistance aux Antibiotiques (laboratoire associé «Entérocoques»), Rennes, France. 5. CHU Clermont-Ferrand, Laboratoire de Bactériologie & CNR de la Résistance aux Antibiotiques, Clermont-Ferrand, France. 6. CNR de la Résistance aux Antibiotiques (laboratoire associé «Entérobactéries: résistance aux C3G et colistine»), Clermont-Ferrand, France. 7. Université Clermont Auvergne, UMR INSERM 1071 USC INRA2018, Clermont-Ferrand, France. 8. CHU de Rennes, Service de Bactériologie-Hygiène hospitalière, Rennes, France.
Abstract
OBJECTIVES: To describe the epidemiological trend of linezolid-resistant enterococci (LRE) collected in France from 2006 to 2016 and to extensively characterize LRE isolates. METHODS: The National Reference Center for Enterococci (NRC-Enc) received enterococcal isolates suspected to be VRE and/or LRE from all French hospitals between 2006 and 2016. LRE isolates were phenotypically characterized and their genomes were entirely sequenced by Miseq (Illumina). Transfer of linezolid resistance was attempted by filter mating experiments. RESULTS: Out of 3974 clinical isolates of enterococci received at the NRC-Enc over the period, 9 (0.2%) were LRE (MICs 8 to >32 mg/L), including 6 Enterococcus faecium and 3 Enterococcus faecalis. This overall prevalence significantly increased over the study period, reaching 0.8% in 2016. The five LRE isolated before 2016 were vanA-positive E. faecium whereas strains isolated in 2016 (one E. faecium and three E. faecalis) were susceptible to vancomycin. None of these isolates was part of an outbreak, while E. faecium strains were assigned to four different STs [17 (1), 80 (3), 412 (1) and 650 (1)] and all three E. faecalis belonged to ST480. Except for the strain isolated in 2010, all LRE were positive for optrA, which was located on plasmids (5/8) or in the chromosome (3/8). Plasmid transfer of optrA was successful in three cases. CONCLUSIONS: There has been a significant increase in the prevalence of LRE in France over time; this is due to the spread of optrA among E. faecium and E. faecalis human clinical isolates (VRE or not).
OBJECTIVES: To describe the epidemiological trend of linezolid-resistant enterococci (LRE) collected in France from 2006 to 2016 and to extensively characterize LRE isolates. METHODS: The National Reference Center for Enterococci (NRC-Enc) received enterococcal isolates suspected to be VRE and/or LRE from all French hospitals between 2006 and 2016. LRE isolates were phenotypically characterized and their genomes were entirely sequenced by Miseq (Illumina). Transfer of linezolid resistance was attempted by filter mating experiments. RESULTS: Out of 3974 clinical isolates of enterococci received at the NRC-Enc over the period, 9 (0.2%) were LRE (MICs 8 to >32 mg/L), including 6 Enterococcus faecium and 3 Enterococcus faecalis. This overall prevalence significantly increased over the study period, reaching 0.8% in 2016. The five LRE isolated before 2016 were vanA-positive E. faecium whereas strains isolated in 2016 (one E. faecium and three E. faecalis) were susceptible to vancomycin. None of these isolates was part of an outbreak, while E. faecium strains were assigned to four different STs [17 (1), 80 (3), 412 (1) and 650 (1)] and all three E. faecalis belonged to ST480. Except for the strain isolated in 2010, all LRE were positive for optrA, which was located on plasmids (5/8) or in the chromosome (3/8). Plasmid transfer of optrA was successful in three cases. CONCLUSIONS: There has been a significant increase in the prevalence of LRE in France over time; this is due to the spread of optrA among E. faecium and E. faecalishuman clinical isolates (VRE or not).
Authors: Lara M Almeida; François Lebreton; Anthony Gaca; Paulo M Bispo; Jose T Saavedra; Rodrigo N Calumby; Luciano M Grillo; Ticiano G Nascimento; Pedro H Filsner; Andrea M Moreno; Michael S Gilmore Journal: Antimicrob Agents Chemother Date: 2020-05-21 Impact factor: 5.191
Authors: Sarah A Egan; Anna C Shore; Brian O'Connell; Grainne I Brennan; David C Coleman Journal: J Antimicrob Chemother Date: 2020-07-01 Impact factor: 5.790
Authors: Camilla Smoglica; Alberto Vergara; Simone Angelucci; Anna Rita Festino; Antonio Antonucci; Fulvio Marsilio; Cristina Esmeralda Di Francesco Journal: Antibiotics (Basel) Date: 2022-02-10
Authors: Stefan Schwarz; Wanjiang Zhang; Xiang-Dang Du; Henrike Krüger; Andrea T Feßler; Shizhen Ma; Yao Zhu; Congming Wu; Jianzhong Shen; Yang Wang Journal: Clin Microbiol Rev Date: 2021-06-02 Impact factor: 50.129
Authors: Philipp Simon; David Busse; David Petroff; Christoph Dorn; Lisa Ehmann; Sophie Hochstädt; Felix Girrbach; Arne Dietrich; Markus Zeitlinger; Frieder Kees; Charlotte Kloft; Hermann Wrigge Journal: J Clin Med Date: 2020-04-09 Impact factor: 4.241
Authors: Lara M Almeida; Anthony Gaca; Paulo M Bispo; François Lebreton; Jose T Saavedra; Rafael A Silva; Irinaldo D Basílio-Júnior; Felipe M Zorzi; Pedro H Filsner; Andrea M Moreno; Michael S Gilmore Journal: Front Public Health Date: 2020-09-24